Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases

Cancer

Volumn 85, Issue 10, 1999, Pages 2160-2169

  Hsueh, Eddy C ^a   Nathanson, Larry ^a   Foshag, Leland J ^a   Essner, Richard ^a   Nizze, J Anne ^a   Stern, Stacey L ^a   Morton, Donald L ^a,b  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Active specific immunotherapy; Delayed response; In transit melanoma; Melanoma vaccine; Regression

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CANCER VACCINE; CIMETIDINE; CYCLOPHOSPHAMIDE; INDOMETACIN; MELANOMA VACCINE; RANITIDINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; REMISSION; SURVIVAL TIME; UNITED STATES;

CANCER VACCINES; HUMANS; MELANOMA; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINATION;

EID: 0033562786     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990515)85:10<2160::AID-CNCR10>3.0.CO;2-0     Document Type: Article

References (26)

1. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997:1947-94.
2. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-5.
3. Singletary SE, Tucker SL, Boddie AW Jr. Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer 1988;61:1437-40.
4. Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL. Natural history and selective management of in transit melanoma. J Surg Oncol 1990;14:146-50.
5. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479-89.
6. Hafstrom L, Rudenstam CM, Blomquist E, Ingvar C, Jonsson PE, Lagerlof B, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991;9:2091-4.
7. Calvo DB III, Patt YZ, Wallace S, Chuang W, Benjamin RS, Pritchard JD, et al. Phase I-II trial of percutaneous intraarterial cis-diamminedichloro platinum (II) for regionally confined malignancy. Cancer 1980;45:1278-83.
8. Morton DL, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-64.
9. Nathanson L. Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rep 1972;56:659-65.
10. Von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988;61:1071-4.
11. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996;6:247-55.
12. Ang KK, Byers RM, Peters LJ, Maor MH, Wendt CD, Morrison WH, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg 1990;116:169-72.
13. Kirkwood JM, Strawderman MH, Emstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
14. Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Famatiga E, Wanek LA, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
15. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al, editors. AJCC cancer staging manual. 5th edition. Philadelphia: Lippincott-Raven, 1997.
16. Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, et al. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994;12:402-11.
17. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in Stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
18. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in Stage II malignant melanoma. Cancer 1992;69:1157-64.
19. Dalgleish A. The case for therapeutic vaccines. Melanoma Res 1996;6:5-10.
20. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-44.
21. Hoon DSB, Okamoto T, Wang HJ, Elashoff R, Nizze JA, Foshag LJ, et al. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 1998;16:1430-7.
22. Dye ES, North RJ. Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression. Transplantation 1984;37:600-5.
23. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985;45:1657-62.
24. Noguchi Y, Richards EC, Chen YT, et al. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995;92:2219-23.
25. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996;93:6291-6.
26. Rankin EM, Kremers B, Gallee M, et al. Immunomodulation following vaccination with autologous GM-CSF transduced and irradiated tumor cells in patients with advanced melanoma. Proc Am Soc Clin Oncol 1997;16:489a.